ATE283478T1 - Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen. - Google Patents

Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.

Info

Publication number
ATE283478T1
ATE283478T1 AT98939016T AT98939016T ATE283478T1 AT E283478 T1 ATE283478 T1 AT E283478T1 AT 98939016 T AT98939016 T AT 98939016T AT 98939016 T AT98939016 T AT 98939016T AT E283478 T1 ATE283478 T1 AT E283478T1
Authority
AT
Austria
Prior art keywords
apoptin
cells
cancer
normal
agents
Prior art date
Application number
AT98939016T
Other languages
English (en)
Inventor
Mathieu Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE283478T1 publication Critical patent/ATE283478T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Measurement Of Current Or Voltage (AREA)
AT98939016T 1997-08-12 1998-08-11 Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen. ATE283478T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (1)

Publication Number Publication Date
ATE283478T1 true ATE283478T1 (de) 2004-12-15

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939016T ATE283478T1 (de) 1997-08-12 1998-08-11 Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.

Country Status (16)

Country Link
US (1) US6528247B1 (de)
EP (1) EP1004021B1 (de)
JP (1) JP4287588B2 (de)
KR (1) KR20010022812A (de)
AT (1) ATE283478T1 (de)
AU (1) AU756587B2 (de)
BR (1) BR9811163A (de)
CA (1) CA2301401C (de)
CZ (1) CZ299874B6 (de)
DE (1) DE69827805T2 (de)
NO (1) NO326659B1 (de)
NZ (1) NZ502800A (de)
PL (1) PL196605B1 (de)
RU (1) RU2214598C2 (de)
SK (1) SK286235B6 (de)
WO (1) WO1999008108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
HUP0202688A2 (en) * 1999-09-02 2002-12-28 Leadd Bv Apoptin-associating protein
AU784723B2 (en) 1999-12-10 2006-06-01 Leadd B.V. Apoptin-associating protein
EP1199363A1 (de) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylationsmodifikationen von Apoptin
EP1377667B1 (de) * 2001-03-30 2008-11-19 Leadd B.V. Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
RU2325200C2 (ru) * 2006-02-20 2008-05-27 Федеральное государственное унитарное предприятие "НПО Астрофизика" Способ лазерного подавления роста и элиминации злокачественных образований
RU2340349C2 (ru) * 2006-08-10 2008-12-10 Геннадий Петрович Македонов Способ стимулирования апоптоза
WO2012091563A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
AU2012316859A1 (en) 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
HU215778B (hu) * 1991-01-15 1999-02-01 Oy Biotie Therapies Ltd. Eljárás szindekántartalom kimutatására biológiai anyagokban, így szövetekben és testnedvekben, a sejtek rosszindulatú transzformációinak jelzésére
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
CZ82692A3 (en) * 1992-03-19 1994-02-16 Prirodovedecka Fakulta Uk Method of testing cyctotoxicity and genotoxicity of chemicals
ES2200065T3 (es) * 1995-06-07 2004-03-01 Leadd B.V. Utilizacion de apoptina.
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0921192A1 (de) * 1997-12-03 1999-06-09 Leadd B.V. Molekulen interagierend mit Apoptin
EP0927757A1 (de) * 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine

Also Published As

Publication number Publication date
CZ2000479A3 (cs) 2000-06-14
DE69827805T2 (de) 2005-12-15
CZ299874B6 (cs) 2008-12-17
KR20010022812A (ko) 2001-03-26
NO326659B1 (no) 2009-01-26
SK286235B6 (sk) 2008-06-06
CA2301401A1 (en) 1999-02-18
JP2001512829A (ja) 2001-08-28
RU2214598C2 (ru) 2003-10-20
EP1004021A1 (de) 2000-05-31
AU8752998A (en) 1999-03-01
WO1999008108A1 (en) 1999-02-18
JP4287588B2 (ja) 2009-07-01
NO20000736L (no) 2000-04-11
EP1004021B1 (de) 2004-11-24
BR9811163A (pt) 2000-07-25
SK1902000A3 (en) 2000-11-07
US6528247B1 (en) 2003-03-04
PL196605B1 (pl) 2008-01-31
AU756587B2 (en) 2003-01-16
CA2301401C (en) 2008-10-21
NZ502800A (en) 2002-10-25
PL338683A1 (en) 2000-11-20
DE69827805D1 (de) 2004-12-30
NO20000736D0 (no) 2000-02-14

Similar Documents

Publication Publication Date Title
DE69807878D1 (de) Erkennung und Modulierung von IAPS und NAIP zur Diagnose und Behandlung von proliferativen Erkrankungen
ATE283478T1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
EP0804074A4 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
ATE226643T1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE257392T1 (de) Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ATE127853T1 (de) Verfahren zur bestimmung der funktionellen wirkung von freiem protein s oder protein c in einer plasmaprobe.
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE241808T1 (de) Verwendungen von apoptin
DE69619683D1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
DE69016858D1 (de) Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
ATE323176T1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE69621837D1 (de) Methoden zur feststellung von alzheimerscher krankheit
ATE260111T1 (de) Mittel zur behandlung von autoimmunkrankheiten
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
ATE8712T1 (de) Diagnostizierverfahren, insbesondere zur frueherkennung von malignen tumoren und/oder viralen erkrankungen und mittel zu seiner durchfuehrung.
ATE75050T1 (de) Reagenzsatz, seine verwendung und diagnostisches verfahren zur bestimmung von humanen pankreasspezifischen proteinen.
IT1270614B (it) Proteine ad attivita' antitumorale da organi di mammiferi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1004021

Country of ref document: EP

REN Ceased due to non-payment of the annual fee